Kancera
  • Svenska
  • Home
  • About us
    • Statement from the CEO
    • Business model
    • Management
    • Board of directors
  • Research&Development
    • R&D portfolio
    • Fractalkine project
      • The problem
      • The solution
      • This is how KAND567 works
      • Next step
      • The future
    • Scientific publications
  • Investors
    • The share
    • Press releases
    • Reports
      • Principles and definitions
    • Calendar
    • Corporate Governance
      • Articles of association
      • General meeting
      • Board of directors committee
      • Board of directors
      • CEO and management
      • Auditors
    • Subscribe
  • Press
    • Press releases
    • Images and logos
    • Subscribe
    • News
    • Press contact
  • Contact
    • Careers
Select Page
  • Svenska
  • Press releases
  • Images and logos
  • Subscribe
  • News
  • Press contact

DRUG DISCOVERY TODAY COVERS KANCERA’S FRACTALKINE PROJECT

2017-04-10

Drug Discovery Today covers Kancera’s Fractalkine project: “Drugs targeted against Fractalkine signaling poised to offer major breakthrough in the treatment of autoimmune diseases and cancer”

Follow this link for the full article.

 

Download our reports here

Read all press releases

Check out the latest news

Click on the image to download our latest report

Kancera AB

Karolinska Institutet Science Park
Nanna Svartz Väg 4
SE-171 65 Solna, Sweden
Tel: +46 (0)850 12 60 80

This site uses cookies. Follow the link below for more information and our web policy:
  • Website policy
  • Svenska
Copyright 2017 Kancera AB